secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2021-08-26T23:59:59+00:00
Accession:  0001193805-21-001224
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.02, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus terminates Providence joint venture; director resigns after Ultragenyx ownership drop
--------------------------------------------------------------------------------

- On Aug 20, 2021, Arcturus received notice from Providence to terminate the Amended and Restated Joint Venture, Research Collaboration and License Agreement; no termination penalties incurred.
- On Aug 25, 2021, director Karah Parschauer resigned from the board effective same day.
- Parschauer was Ultragenyx's nominee; her departure follows Ultragenyx's stock sales reducing its ownership below the contractual threshold.
- Company continues collaboration with Ultragenyx; board will remain at six members until a replacement is identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380521001224/0001193805-21-001224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380521001224/e620900_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-21-001224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer